Investigational Studies

According to a forecast report by Arcview Market Research, growth in the legal cannabis market will re-accelerate in the beginning of 2018, as adult use (recreational use) sales are expected to ramp up in Canada, California, and Massachusetts along with medical sales in Florida. The market is expected to grow from the $6.7 billion market […]

by

TORONTO, ONTARIO–(Marketwired – Sept. 27, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation […]

by

By Alicia Wallace, The Cannabist Staff Cannabidiol is a non-psychoactive cannabis compound touted for its medicinal promise — but marijuana- and hemp-derived extracts rich in CBD and low in intoxicating THC are facing a future yet to be determined. The Cannabist’s special report “CBD, TBD” explores the issues with CBD — federal-state conflicts, national drug […]

by

A market report by Ameri Research Inc. indicates that the global legal cannabis market was valued at $14.3 billion in 2016 and is projected to grow at a CAGR of 21.1% from 2017 to 2024. During the forecast period, the projected demand of cannabis will continue to rise for both recreational and medical use with estimated global […]

by

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. … read more at: https://www.thepharmaletter.com/article/zx008-meets-phase-iii-goals-in-dravet-syndrome-trial

by

By Michael FitzhughStaff Writer Positive new pivotal data has shown that ZX-008, Zogenix Inc.’s re-imagining of a key component of the ill-fated obesity drug Fen-Phen, can significantly reduce seizure frequency in children with the rare genetic epilepsy, Dravet syndrome. The result kept Zogenix on track to seek U.S. and European approvals for the drug in […]

by

Dive Brief: Zynerba Pharmaceuticals’ shares shot up by 52.5% after news on Thursday that its lead drug, ZYN002 cannabidiol gel met its primary endpoint in its FAB-C Phase 2 trial in children and adolescents with Fragile X syndrome. In the open label study of the orphan drug, patients had a 46% improvement from baseline on […]

by

ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced positive […]

by

TORONTO, ONTARIO–(Marketwired – Sept. 27, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation […]

by

GW Pharmaceuticals is closing in on a US filing for its cannabinoid epilepsy drug, Epidiolex, after trumpeting late-stage study findings. The company specialises in drugs derived from the cannabis plant, and noted that the New England Journal of Medicine had published results from its phase 3 study of Epidiolex (cannabidiol) in the rare childhood epilepsy, Dravet Syndrome. […]

by